Sigma-Aldrich Fine Chemicals has promoted Michael Harris to head of business development in Europe, Mike Czarny to director of sales in the US, and Andreas Weiler to the post of head of project management and technology transfer at SAFC Pharma, the rebranded unit that combines Sigma’s Ultrafine and Tetrionics units. Harris, previously head of business development at Ultrafine, will be responsible for the recruitment and organization of the SAFC Pharma business development team, planning and implementation of the sales strategy and all other general sales activities, the company said. Czarny was previously vice president of business development for Tetrionics.
Judith Swain, chairman of the department of medicine at Stanford University, has been named the first director of the College of Integrated Life Sciences at the University of California at San Diego, the school announced recently. She will head a new multidisciplinary program that is based within the university’s health sciences department and is designed to facilitate translational research, and the training of physicians, pharmacists, and medical researchers.
Gov. Arnold Schwarzenegger of California nominated Robert Klein, a real estate developer and a financial backer of California’s stem cell research initiative, as chairman of the Independent Citizens Oversight Committee, a 29-member committee that will oversee the state’s $3 billion allocation based on bond sales. Edward Penhoet, co-founder and former chief executive officer of Chiron, was nominated as vice chairman. The committee will guide the work of the new California Institute for Regenerative Medicine, which holds its first meeting on Friday in San Francisco.
Daniel Webster Jr. has been appointed interim president of Camtronics Medical Systems. Webster previously was president, CEO, and chairman of Quest Technologies, and before that, a division manager with PerkinElmer.
Harold Ingalls, CFO of Serologicals, has been named to the board of directors of Metaphore Pharmaceuticals of Fort Lee, NJ. He will serve on the audit and corporate governance committees, the company said in a statement.
Michael Klein was named as president and CEO of Xoft of Fremont, Calif. Klein previously was president and CEO of R2 Technology and before that was general manager of Varian’s medical systems oncology business. Previously, he was vice president of sales and marketing for BD Medical’s North American sales and marketing.
Mike Leavitt, chief of the Environmental Protection Agency, this week was nominated to serve as secretary of the US Department of Health and Human Services. The former Republican governor of Utah may have to restructure his personal investment portfolio if he is approved by Congress as he holds shares in Johnson & Johnson, Medtronic, Merck, and Agilent Technologies, according to the Salt Lake City Tribune newspaper. He also has a large stake in his family’s Leavitt Group Enterprises, which owns 100 independent insurance agencies, the newspaper said.
Charles Swindell joined Phyton Biotech of Ithaca, NY, as vice president of research and development, the plant cell culture technology company said last week. Swindell will manage the transition of Phyton, a subsidiary of DFB Pharmaceuticals, into a fully integrated biotechnology company. Swindell previously was chairman of the department of chemistry at Bryn Mawr College.